Merck Claimed Company
At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world ā and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. read more
HR or Marketing? Claim Your Free Employer Account
Mark D. Erion Ph.D. ā Head of Worldwide Basic Franchise Diabetes & Obesity and Vice President at Merck
Executive Bio
Dr. Mark D. Erion, Ph.D., has been the Head of Worldwide Basic Franchise Diabetes & Obesity and Vice President of Merck & Co., Inc. since September 2009. Dr. Erion has been the Chief Scientific Officer of Metabasis Therapeutics Inc. since November 2005. He co-founded Metabasis Therapeutics Inc. and served as its Chief Executive Officer and President from December 2008 to October 31, 2009. He served as Vice President and Worldwide Basic Franchise Head of Diabetes and Obesity at Metabasis Therapeutics. He served as an Executive Vice President of Research and Development from April 1997 to December 2008. Prior to joining Metabasis Inc., Dr. Erion was with Gensia, where he served as Director of Chemistry and Biochemistry from 1991 and assumed responsibility for research in 1996. Prior to joining Gensia, Dr. Erion was a Group Leader at Ciba-Geigy Pharmaceutical Company, from where he directed a team in the area of protein engineering. He has been a Director of Metabasis Therapeutics Inc. since June 1999. Dr. Erion served as a Member of the Scientific Advisory Board of Tocagen Inc. Dr. Erion's research has resulted in over 80 publications and 25 U.S. patents. His discovery efforts over the past 12 years have produced seven clinical candidates, several research collaborations and served at Metabasis Therapeutics HepDirect and NuMimetic technologies. Dr. Erion received a B.S. in Mathematics and Chemistry from the University of Oregon, a Ph.D. in Chemistry from Cornell University and was a National Institutes of Health Postdoctoral Fellow in Enzymology at the Massachusetts Institute of Technology.
Executive Team Culture Ratings from Merck Employees
TOP
20%
Merck's Executive Team scores in the Top 20%
of similar sized companies on Comparably
of similar sized companies on Comparably
Merck's Executive Team at a Glance
Based on 219 ratings, Merck's employees are satisfied with their Executive Team and give them a āB+ā or 74/100. On average, Men provided higher ratings for their Executive Team compared to Women. Also, the HR department thinks more highly of the Executive Team relative to the IT department.
Merck's Executive Team ranks in the Top 30% of other companies in New York and Top 20% of other companies on Comparably that also have 10,000+ Employees.
×